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•	 Does surgery Improve 
survival of Patients 
with Malignant Pleural 
Mesothelioma? A 
Multicenter Retrospective 
Analysis of 1365 
Consecutive Patients
To assess the effect of surgical treatment with pleurectomy/
decortication (P/D) or extrapleural pneumonectomy (EPP) on the 
outcome of patients with malignant pleural mesothelioma (MPM), 
a multicenter retrospective study of 1365 consecutive patients with 
MPM was conducted. Patients were given chemotherapy alone (n 
= 172) or palliative care (n = 690) or surgery (P/D, n = 202 or EPP, 
n = 301) with or without chemotherapy. Among 16.8% of patients 
who were alive after a median follow-up of 6.7 years, median 
BRIeF RePORt
•	 hIP1-ALK, A novel Fusion 
Protein Identified in Lung 
Adenocarcinoma
In addition to the five fusion proteins anaplastic lymphoma kinase 
(ALK)–EML4, –TFG, –KIF5B, –KCL1, and –PTPN3 reported to 
be involved in ALK overexpression and activation in non– small-cell 
lung cancer, Hong and colleagues discovered a novel fusion gene, 
huntingtin interacting protein 1 (HIP1)–ALK. Reverse transcriptase 
polymerase chain reaction and immunohistochemistry were used in 
In thIs Issue
survival was 11.7 months for those who received 
palliative care, 20.5 months for chemotherapy alone, 
and 18.8 months for P/D and EPP. The 30-day mortality 
after P/D and EPP was 2.6% and 4.1%, respectively 
(p = 0.401). Epithelial histology and chemotherapy 
were independent favorable prognostic factors. Among 
131 patients with all the favorable prognostic factors, 
the findings showed that median survival was similar 
between those receiving chemotherapy only (18.6 
months), P/D (24.6 months), and EPP (20.9 months) 
(p = 0.596). The authors concluded that, though 
no significant improvement in patient survival was 
observed with surgery, further evaluation of the modest 
benefit after surgery versus chemotherapy is warranted. 
In addition, investigating MPM patients with good 
prognostic factors, who receive P/D after induction 
chemotherapy versus chemotherapy alone, in a large 
multicenter randomized trial is required. (p. 383)
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the detection of this fusion gene and protein expression, 
respectively. It was localized to the cytoplasm, mainly 
in the submembrane area. HIP1 is essential for clathrin 
trafficking and cell survival in relation to its epsin 
N-terminal homology–domain. The coiled-coil domain 
of HIP1 and the juxtamembrane of ALK on the fusion 
protein demonstrated potential constitutive dimerization 
and aberrant activation of the ALK tyrosine kinase 
activity, which could indicate strong transforming 
potential. This case report presented HIP1–ALK as a 
novel diagnostic and therapeutic candidate for lung 
adenocarcinoma, which warrants further studies. (p. 412)
•	 RAnKL Inhibition Blocks 
Osteolytic Lesions and 
Reduces skeletal tumor 
Burden in Models of non–
small-Cell Lung Cancer 
Bone Metastases
RANK ligand (RANKL), crucial for osteoclasts and skeletal 
destruction because of bone metastasis, is believed to be involved 
in tumor cell–mediated osteolysis, which is yet to be confirmed 
in the case of non–small-cell lung cancer (NSCLC). The authors 
evaluated the effects of RANKL inhibition by using human 
osteoprotegerin-Fc (OPG-Fc), either alone or in combination with 
docetaxel, on osteolysis, skeletal tumor burden, and survival in 
two novel mouse models of NSCLC bone metastasis. 
Mice bearing skeletal NSCLC tumors were treated with 
OPG-Fc and tumor progression was monitored using 
radiography, longitudinal bioluminescent imaging, and 
histology. The results from both NSCLC bone metastasis 
models showed that RANKL inhibition reduced 
osteolytic lesions and skeletal tumor progression. 
This observation was associated with reduced tumor-
associated osteoclasts. These findings indicated that 
RANKL is needed for tumor-mediated osteolytic bone 
destruction in NSCLC cells in vivo. The effect of 
RANKL inhibition on skeletal tumor progression could 
be a result of indirect suppression of tumor-mediated 
osteoclastogenesis hence blocking the release of growth 
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•	 Impact of extratumoral 
Lymphatic Permeation 
on Postoperative survival 
of non–small-Cell Lung 
Cancer Patients
Lymphatic permeation has been a prognostic factor for patients 
with resected non–small-cell lung cancer and the authors set 
out to evaluate its survival impact in these patients based on its 
location, which is in this study, in extratumoral area. From the 
long-term follow-up data (2001–2006), 1069 consecutive patients 
with resected NSCLC were analyzed and categorized by absence 
of (ly0), intratumoral (ly1), and extratumoral (ly2) lymphatic 
factors and calcium from the bone microenvironment. 
In addition, significantly enhanced inhibition of skeletal 
tumor growth was observed in OPG-Fc plus docetaxel 
compared with either agent alone. To conclude, this 
in vivo study provided solid evidence supporting the 
antitumor effect and a survival advantage of RANKL 
inhibition in NSCLC. It also indicated the therapeutic 
potential of targeting bone environment to achieve better 
outcomes in patient, which warrants further clinical 
studies. (p. 345)
permeation. Majority of the patients (79%) showed 
no lymphatic permeation; 12% were ly1 whereas 9% 
were ly2. Ly2 has a higher incidence in patients with 
advanced disease and intrapulmonary metastases, and 
significantly worse 5-year overall survival rate (34%) 
versus ly0 (75%, p<0.01) and ly1 (63%, p<0.01). 
The findings also demonstrated ly2 as an independent 
poor prognostic factor (hazard ratio, 1.73; p < 0.01). 
There was no significant difference in overall survival 
and recurrence-free survival between the different pT 
status of tumor where ly2 was present: T1 and T2 (p 
= 0.43 and p = 0.94, respectively) and T3 (p = 0.77 
and p = 0.94, respectively). This study demonstrated a 
marked difference in the adverse prognostic impact of 
lymphatic permeation based on its intra-/extratumoral 
locations. It therefore underscores the importance of 
assessing locations of lymphatic permeation in resected 
NSCLC patients. (p. 337)
ReseARCh WAtCh
•	 structural, Biochemical, 
and Clinical 
Characterization of 
epidermal Growth Factor 
Receptor (eGFR) exon 20 
Insertion Mutations in 
Lung Cancer
Although epidermal growth factor receptor (EGFR) mutations 
(G719X, exon 19 deletions/insertions, L858R, and L861Q) are 
associated with sensitivity to EGFR tyrosine kinase inhibitors 
(TKIs) in advanced non–small cell lung cancer (NSCLC), EGFR 
exon 20 insertion mutations are associated with insensitivity 
to TKIs. This study evaluated the mechanism of this primary 
resistance by investigating a range of exon 20 insertion mutations 
in vitro for TKI sensitivity and comparing it with patients’ 
responses to gefitinib and erlotinib. The findings showed that most 
of these exon 20 mutations were resistant to EGFR TKIs. Analysis 
of the crystal structure demonstrated that the TKI-insensitive 
mutant (D770_N771insNPG) adopts a structure of 
adenosine triphosphate–binding pocket and the helix, 
which helps the active kinase conformation, and 
activates EGFR by not enhancing its affinity for EGFR 
TKIs. Interestingly, a novel mutation EGFR-A763_
Y764insFQEA uncovered in this study was shown to 
be highly sensitive to EGFR TKIs in vitro. Its presence 
in NSCLC patients was associated with response to 
erlotinib. Further evaluation of this mutant revealed an 
altered structure in area affected by the TKI-sensitive 
EGFR-L858R. The results of this study demonstrated 
complex and detailed interplay between EGFR 
mutations and their response to EGFR TKIs. It also 
guides the treatment of NSCLC harboring EGFR exon 
20 insertion mutations.
Yasuda H, Park E, Yun C-H, et al. Structural, 
biochemical, and clinical characterization of 
epidermal growth factor receptor (EGFR) exon 20 
insertion mutations in lung cancer. Sc Translat Med 
2013;5:216ra177.
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•	 Balancing Curability and 
unnecessary surgery in 
the Context of Computed 
tomography screening for 
Lung Cancer
This report revealed the findings on surgical management in 
computed tomography (CT) screening for lung cancers from a 
large ongoing screening program, International Early Lung Cancer 
Action Program for the U.S. sites. Of 31,646 baseline and 37,861 
annual repeat CT screenings, 492 patients who underwent surgical 
resection were identified. Of the 89% diagnosed with lung cancer 
and underwent surgery, 91% had clinical stage I disease. Fifty-four 
patients with nonmalignant disease had sublobar (48) and lobectomy 
(6) resection. All 428 lung cancer patients (excluding 9 with typical 
carcinoids) demonstrated an estimated cure rate of 84% according 
to the 15-year Kaplan–Meier survival, and 88% for clinical stage 
•	 Prediction of survival in 
Resected non–small-Cell 
Lung Cancer using a 
Protein expression Based 
Risk Model: Implications 
for Personalized 
Chemoprevention and 
therapy
The authors developed a novel risk model in predicting recurrence 
of disease in patients with resected non–small-cell lung cancer 
by incorporating clinical data and biomarkers from archival 
tissues (2002–2005). Immunohistochemistry was used to examine 
expression of 21 proteins relevant to lung carcinogenesis determined 
in previous studies. The effects of clinical factors and biomarkers 
on recurrence-free survival (RFS) and overall survival (OS) were 
estimated by Cox models. After a median follow-up of 5.3 years of 
370 patients, median OS is 6.4 years with 209 recurrences or death. 
I tumor resected within 1 month of diagnosis. When 
comparing the results before and after the National Lung 
Screening Trial, there was a significant increase in video-
assisted thoracoscopic surgery (from 10% to 34%, p < 
0.0001) and sublobar resection (from 22% to 34%, p = 
0.01). However, no significant differences were observed 
in malignant diagnoses, clinical stage I, pathologic stage, 
tumor size, and cell type. The authors concluded that in 
CT screening, the frequency and extent of surgery for 
nonmalignant disease could be reduced and give lung 
cancer patients undergoing surgery resection a high cure 
rate.
Flores R, Bauer T, Aye R, et al. Balancing  
curability and unnecessary surgery in the context 
of computed tomography screening for lung 
cancer. J Thorac Cardiovasc Surg, doi:10.1016/j.
jtcvs.2013.11.001 (2013).
The findings revealed enhanced expression of pAMPK, 
pmTOR, EpCAM, and CASK to be significant predictors 
for favorable RFS (p<0.05) whereas insulin receptor, 
CXCR2, and IGF1R were predictors for unfavorable 
RFS. Also, pAMPK, pmTOR, and EpCAM predicted 
for favorable OS (p<0.05) whereas CXCR2 and FEN1 
for unfavorable OS. The development of this risk model 
for tumor recurrence and survival in patients with 
resected NSCLC could help improve personalization of 
chemoprevention and therapy, for instance, identifying 
patients with poor prognosis for novel treatments in 
clinical trials and sparing those with good prognosis 
from chemotherapy toxicities.
Gold KA, Kim ES, Liu D, et al. Prediction of 
survival in resected non-small cell lung cancer using a 
protein-expression based risk model: Implications for 
personalized chemoprevention and therapy. Clin Canc 
Res doi:10.1158/1078-0432.CCR-13–1959 (2013).
•	 tecemotide (L-BLP25) 
versus Placebo after 
Chemoradiotherapy for 
stage III non–small-
Cell Lung Cancer 
(stARt): A Randomized, 
 Double-Blind, Phase 3 trial
A randomized, double-blind phase III (START) was conducted to 
evaluate tecemotide (MUC1-specific immunotherapy) in improving 
survival of patients with stage III unresectable non–small-cell lung 
cancer as a maintenance therapy after chemoradiation. Patients 
were randomized to tecemotide (829) and placebo (410). The 
findings showed no significant difference in overall 
survival between the tecemotide arm and the placebo 
arm in all patients: 25.6 months tecemotide versus 22.3 
months placebo (adjusted hazard ratio [HR] 0.88; p = 
0.123). Median overall survival for patients receiving 
prior concurrent chemoradiotherapy was 30.8 months 
tecemotide versus 20.6 months placebo (adjusted HR 
0·78; p = 0·016), whereas that for patients receiving 
sequential chemoradiotherapy was 19.4 months 
tecemotide versus 24.6 months placebo (adjusted 
HR 1·12; p = 0·38). Grade 3 or 4 and serious adverse 
events were found in both groups, including dyspnoea, 
pneumonia and metastasis to central nervous system. 
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No difference was found in immune-related adverse 
events between the two groups. Although tecemotide 
administration after chemoradiotherapy did not improve 
survival in the study population, the authors suggest 
potential benefits in patients previously receiving 
concurrent chemoradiotherapy, which warrants further 
investigation in this population.
Butts C, Socinski MA, Mitchell PL, et al. 
Tecemotide (L-BLP25) versus placebo after 
chemoradiotherapy for stage III non-small-cell lung 
cancer (START): a randomised, double-blind, phase 3 
trial. Lancet Oncol 2013;15:59–68.
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•	 AACR-IAsLC Joint 
Conference on the 
Molecular Origins of Lung 
Cancer: e-Cigarettes May 
Lead to Lung Cancer in 
high-Risk Individuals
E-cigarettes have been known as a relatively safe alternative to 
tobacco cigarettes but studies on their effect on lung function and 
lung carcinogenesis are scarce. A preclinical study investigated 
human bronchial epithelial cell harboring mutant TP53 and 
KRAS genes and demonstrated that e-cigarette vapor promoted 
carcinogenicity of the cells, similar to tobacco smoke. The findings 
•	 AACR-IAsLC Joint 
Conference on the 
Molecular Origins of 
Lung Cancer: Improved 
Outcomes in Advanced 
Lung Cancer Patients 
with Imprime PGG Plus 
Chemotherapy
Imprime PGG is an immunotherapy that directs the immune 
system to kill monoclonal antibody targeted cancer cells. High 
number of antibodies present to bind Imprime PGG to the immune 
cells leads to the activation of high number of these cells to 
recognize and kill cancer cells. These antibodies in the serum 
were quantified and the levels were used to categorize patients as 
biomarker positive or negative. A phase II study randomized 90 
patients with stage IIIB or IV non–small-cell lung cancer to control 
+ cetuximab (n = 30), and to Imprime PGG + cetuximab (n = 60). 
were presented at the AACR-IASLC Joint Conference 
on the Molecular Origins of Lung Cancer in San 
Diego. However, cancerous behaviors did not develop 
in immortalized human bronchial epithelial cells with 
normal TP53 and KRAS genes exposed to high-nicotine 
level from e-cigarette vapor, which was toxic to the 
cells. The preliminary results suggest that e-cigarette 
vapor is likely to cause lung cancer in former or current 
smokers who are at high risk for lung cancer because 
of the presence of mutations. Further studies include 
analysis of e-cigarettes induced genetic profiles versus 
those related to lung carcinogenicity to dissect the role 
of e-cigarette in malignant transformation of lung. 
The findings should serve as guidance to the Food and 
Drug Administration on the physiological effects of 
e-cigarettes.
In addition, carboplatin and paclitaxel were given to all 
patients. In the Imprime PGG arm, 15 were  biomarker-
positive whereas 31 were biomarker-negative among 
46 patients evaluable for endpoints. Median overall 
survival of the two arms were similar,that is, 11.2 
months and 10.2 months, respectively. Within the 
Imprime PGG arm, biomarker-positive patients showed 
extended median overall survival of 16.5 months 
versus 9.1 months in biomarker-negative patients. 
Furthermore, 17% of these biomarker-positive patients 
survived for 3 years post-treatment but none of the 
biomarker-negative patients achieved that. The findings 
showed that adding Imprime PGG into chemotherapy 
with carboplatin, paclitaxel, and cetuximab benefited 
biomarker-positive patients with late-stage non–small-
cell lung cancer (improved response rates and overall 
survival), with a good safety profile (cytotoxics or 
cetuxima-relevant toxicities: 86% in control arm versus 
78% in Imprime PGG arm).
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•	 FDA Grants Dabrafenib 
Breakthrough therapy 
Designation for  
BRAF-Mutated nsCLC
Dabrafenib (Tafinlar) has been granted Breakthrough 
Therapy designation by the Food and Drug 
Administration for the treatment of patients with 
metastatic non–small-cell lung cancer harboring BRAF 
V600E mutation, and have received previous  platinum-
containing chemotherapy. BRAF V600E mutation is 
found in approximately 2% of patients with non– small-
cell lung cancer. This designation was based on the 
results from an ongoing phase II trial of dabrafenib in 
this patient population, which were presented at the 
2013 ASCO Annual Meeting.
